AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33299898
Drug: Second IVIG
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second IVIG treatment
Trial: 36194219
Drug: Opioid-sparing protocol
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-sparing protocol (naproxen, acetaminophen, pantoprazole, limited hydromorphone, educational infographic)
Trial: 36194219
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (opioid analgesic)
Trial: 32702101
Drug: Meloxicam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (15 mg per day) for 4 weeks followed by 10 weeks of meloxicam
Trial: 35318752
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant with immediate provisional restoration and socket preservation
Trial: 35318752
Drug: Early implant
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early implant placement with guided bone regeneration and delayed loading
Trial: 32324435
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg intravenously on days 1 and 15, surgery planned on day 29.
Trial: 32890015
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.9% saline infusion)
Trial: 35695753
Drug: Intrathecal 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal 2-chloroprocaine 40 mg in Group 1
Trial: 35695753
Drug: Intrathecal 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal 2-chloroprocaine 35 mg in Group 2
Trial: 35695753
Drug: Intrathecal 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal 2-chloroprocaine 45 mg in Group 3
Trial: 35695753
Drug: Intrathecal 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal 2-chloroprocaine (varied doses based on CRM)
Trial: 33714527
Drug: oAPBI (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oAPBI (once daily)
Trial: 33714527
Drug: tAPBI (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tAPBI (twice daily)
Trial: 32741071
Drug: Oxycodone 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.025 mg/kg
Trial: 32741071
Drug: Oxycodone 0.050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.050 mg/kg
Trial: 32741071
Drug: Oxycodone 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.075 mg/kg
Trial: 32741071
Drug: Oxycodone 0.100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.100 mg/kg
Trial: 35092948
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (1000 IU tablet)
Trial: 33637409
Drug: Tablet computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet computer game (n = 30)
Trial: 33637409
Drug: Standard departmental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard departmental preparation (n = 30)
Trial: 34649534
Drug: perinatal specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perinatal specific cognitive behavioural therapy (CBT)
Trial: 34660501
Drug: Free oral
RxNorm normalized name: CariFree Oral Paste Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free oral HIV self-test kits (HIVST) offered to participants
Trial: 34660501
Drug: Free oral
RxNorm normalized name: CariFree Oral Paste Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free oral HIV self-test kits (HIVST)
Trial: 35817957
Drug: Metformin (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (425 mg/d for 2 years, then 850 mg/d for 2 years)
Trial: 34029880
Drug: Online psychosocial
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online psychosocial intervention adjunctive to an activity monitor (Fitbit)
Trial: 35395953
Drug: Personalized and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized and home-based speech therapy for 8 weeks
Trial: 32333541
Drug: Medication (Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Prednisone acetate, Acyclovir, Vitamin B12, Vitamin B1)
Trial: 32776425
Drug: Immune suppression
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune suppression therapy (IST)
Trial: 34883037
Drug: Tailored therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored therapy (TT)
Trial: 34883037
Drug: PAM-B therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAM-B therapy
Trial: 34700258
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy to Prevent Suicide (MBCT-S)
Trial: 34877858
Drug: Topical 0.3%
RxNorm normalized name: triclosan topical 0.3% topical bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.3% amphotericin B in 30% dimethyl sulfoxide cream
Trial: 34877858
Drug: 30% dimethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% dimethyl sulfoxide cream (vehicle cream)
Trial: 34270689
Drug: 400 g
RxNorm normalized name: Ambi 60 PSE-400 GFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 g of intrusive force per segment (40 g per root)
Trial: 34270689
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g of intrusive force per segment (20 g per root)
Trial: 33164956
Drug: Neurodevelopmental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodevelopmental treatment (NDT) exercises
Trial: 34503682
Drug: IL-2 treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IL-2 treatment in T-cell-deficient mice
Trial: 34105231
Drug: Ridge splitting
RxNorm normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridge splitting with simultaneous implant placement using patient specific guides (PSGs)
Trial: 35691565
Drug: Postmenopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmenopausal hormone (PMH) use
Trial: 34347860
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every other week
Trial: 35749144
Drug: Helichrysum italicum
RxNorm normalized name: HELICHRYSUM ITALICUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helichrysum italicum infusion (HI)
Trial: 35749144
Drug: Helichrysum arenarium
RxNorm normalized name: HELICHRYSUM ARENARIUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helichrysum arenarium infusion (HA)
Trial: 32332617
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention (self-management of antihypertensive medication, self-measurement of blood pressure, hypocaloric and low sodium diet, and physical exercise)
Trial: 34085115
Drug: Vonoprazan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan (10 mg/day)
Trial: 34085115
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (100 mg/day) with additional PPI (either esomeprazole or vonoprazan)
Trial: 33764445
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) 400 μg/m2/day for 5 days via intravenous infusion
Trial: 33768619
Drug: Nitazoxanide 500
RxNorm normalized name: nitazoxanide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 500 mg twice daily for 24 weeks
Trial: 33768619
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg twice daily for 24 weeks
Trial: 35798534
Drug: Ustekinumab (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (intravenous infusion 6 mg/kg at week 0, followed by subcutaneous injections of 90 mg at week 8 and every 8 weeks)
Trial: 36041126
Drug: MSC suspension
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC suspension added to the graft (Group 2)
Trial: 35943745
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (2.0 μg/kg)
Trial: 34385543
Drug: Durvalumab and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab and pomalidomide combination therapy
Trial: 36301724
Drug: Propofol‐based total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol‐based total intravenous anesthesia (TIVA)
Trial: 32684486
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO, 6 g fish oil, 3.85 g EPA & DHA)
Trial: 32684486
Drug: Coconut oil
RxNorm normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut oil + fish oil (COFO, 18.65 g coconut oil, 15 g MCSFA + 6 g fish oil, 3.85 g EPA & DHA)
Trial: 32684486
Drug: Coconut oil
RxNorm normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut oil (CO, 18.65 g coconut oil, 15 g MCSFA)
Trial: 34061883
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment delivered by multidisciplinary teams at opioid agonist treatment clinics or community care centers, including on-site testing for HCV, liver fibrosis assessment, counseling, treatment, and posttreatment follow-up.
Trial: 34061883
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment delivered in hospital outpatient clinics.
Trial: 34590334
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) ghrelin infusion (3 µg/kg loading dose followed by 16.9 ng/kg/min continuous infusion)
Trial: 34883036
Drug: Sequential IPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential IPC regimen
Trial: 34883036
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (LymphAssist and Sequential IPC)
Trial: 34863622
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural block (CEB) with GA, 0.2% ropivacaine 1 ml/kg (n=25)
Trial: 35777410
Drug: 6-month PrEP
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month PrEP dispensing plus interim oral fluid-based HIVST (with biannual clinic visits)
Trial: 36164947
Drug: Omalizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (300 mg/month, min-max=150-1200 mg)
Trial: 36164947
Drug: Mepolizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (300 mg/month for 2 patients with EGPA)
Trial: 36164947
Drug: Biological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological treatment interruption
Trial: 36164947
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of biological use
Trial: 33822368
Drug: Daratumumab in
RxNorm normalized name: daratumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab in combination with lenalidomide and dexamethasone (D‐Rd)
Trial: 34230150
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NACT) with TIP (cisplatin, ifosfamide, paclitaxel)
Trial: 34230150
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NACT) with TIP (cisplatin, ifosfamide, paclitaxel) followed by total mesometrial resection (TMMR) and adjuvant chemotherapy (ACT)
Trial: 35604179
Drug: Self-made acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-made acne prescription taken orally
Trial: 35604179
Drug: Chinese patent
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese patent medicine Qingre Anchuang taken orally (Control)
Trial: 34364382
Drug: Nomograms for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomograms for overall survival (OS) and cancer-specific survival (CSS) based on independent prognostic factors including age, sex, tumor size, grade, chemotherapy, N stage, and M stage.
Trial: 35476124
Drug: Electronic tool
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic tool to detect and reduce complexity of drug treatment
Trial: 33206382
Drug: 8U/kg abobotulinumtoxinA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8U/kg abobotulinumtoxinA injections
Trial: 33206382
Drug: 16U/kg abobotulinumtoxinA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16U/kg abobotulinumtoxinA injections
Trial: 35688588
Drug: Nurse-led peer
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led peer support intervention (6 weekly peer support sessions facilitated by a nurse and at least one peer facilitator)
Trial: 35688588
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (weekly individual face-to-face sessions for 6 weeks)
Trial: 33080005
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg up to 800 mg, intravenous within 8 hours from randomization, followed by a second dose after 12 hours)
Trial: 35213716
Drug: Histamine-2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-2 receptor blockers
Trial: 32185993
Drug: Pricking and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pricking and penetrating moxibustion therapy
Trial: 32185993
Drug: Penetrating moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penetrating moxibustion therapy (Control)
Trial: 32078683
Drug: 0.40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.40 mg/kg tenecteplase (maximum, 40 mg; n = 150)
Trial: 32078683
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg tenecteplase (maximum, 25 mg; n = 150)
Trial: 32078683
Drug: 0.40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.40 mg/kg tenecteplase
Trial: 32740347
Drug: Beta-blocker (BB)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker (BB)
Trial: 35493500
Drug: Remdesivir, hyperimmune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remdesivir, hyperimmune plasma, and corticosteroids (treatment during flares)
Trial: 32788067
Drug: Prednisolone treatment
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone treatment for Bell's palsy
Trial: 35218604
Drug: Trazpiroben 25
RxNorm normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazpiroben 25 mg alone
Trial: 35218604
Drug: Trazpiroben 25
RxNorm normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazpiroben 25 mg with esomeprazole 40 mg
Trial: 32223086
Drug: Tadalafil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (5 mg) plus tamsulosin hydrochloride (0.2 mg)
Trial: 32223086
Drug: Tadalafil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (5 mg) only
Trial: 32086898
Drug: Spirolactone 20
RxNorm normalized name: spironolactone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirolactone 20 mg orally twice a day for 7 days after H-UPPP
Trial: 34282866
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser treatment every 2 months for a total of 3 sessions
Trial: 33590901
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nitazoxanide, ribavirin, and ivermectin plus Zinc supplement
Trial: 32315461
Drug: Drug Burden
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Burden Index (DBI) assessment
Trial: 32092717
Drug: Bisoprolol patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol patch
Trial: 33010934
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg of palonosetron (Group 1)
Trial: 33010934
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of ondansetron associated with 4 mg of dexamethasone (Group 2)
Trial: 33010934
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of dexamethasone (Group 3)
Trial: 36443585
Drug: Phloroglucinol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloroglucinol (oral or IV/IM)
Trial: 36443585
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (dexketoprofen for urinary spasms and pain; metamizole or scopolamine for biliary colic)
Trial: 36484189
Drug: Celecoxib capsules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib capsules, 0.2 g twice a day (medication group)
Trial: 33009349
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (350 mg·d ‐1 , 10 days)
Trial: 33771903
Drug: high-dose octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose octreotide LAR
Trial: 32323462
Drug: Peeling with
RxNorm normalized name: orange peel extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peeling with 70% glycolic acid followed by 5% 5-fluorouracil cream
Trial: 32323462
Drug: 5% 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluorouracil cream (twice daily)
Trial: 35686572
Drug: V-01 vaccine
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: V-01 vaccine
Trial: 34247582
Drug: Physical exercises
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercises with elements of dance movement therapy (DMT), 30-min session, two times a week for 12 weeks
Trial: 33605029
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 or 200 mg/day for 5 days)
Trial: 33605029
Drug: Triamcinolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (40 mg in a single injection)
Trial: 34776136
Drug: Foam pad
RxNorm normalized name: BARRIER,FOAM PAD TORBOT #431R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foam pad balance exercises (60 min/day, twice/week for 6 weeks)
Trial: 33974170
Drug: tDCS combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS combined with conventional comprehensive treatment
Trial: 33974170
Drug: Conventional comprehensive
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional comprehensive treatment
Trial: 36006613
Drug: Therapeutic-dose bodyweight-adjusted
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose bodyweight-adjusted oral rivaroxaban (n=40)
Trial: 36006613
Drug: Standard anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticoagulation with heparins, with or without vitamin K antagonists (n=16)
Trial: 32034016
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg orvepitant
Trial: 32034016
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg orvepitant
Trial: 36108603
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia prior to mydriatic drops
Trial: 34606529
Drug: Exogenous ketone
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous ketone supplement (β‐hydroxybutyrate)
Trial: 35686380
Drug: Celecoxib-tramadol co-crystal
RxNorm normalized name: celecoxib / tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib-tramadol co-crystal (CTC) 200 mg every 12 h
Trial: 35686380
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg every 6 h
Trial: 35686380
Drug: Celecoxib 100
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 100 mg every 12 h